FDA Approves ORLADEYO Oral Pellets for Adults and Teens With HAE
BCRX sits 29% above its 52-week low of $6.23 on elevated volume (1.9× avg).
Summary
The FDA approved BioCryst's supplemental NDA for the 150 mg oral pellet formulation of ORLADEYO in adults and adolescents 12 and older, letting patients take the once-daily HAE prophylaxis as a pellet instead of a capsule. This extends the pellet option beyond the 2-to-under-12 pediatric population cleared in December 2025, so ORLADEYO is now the only targeted oral prophylactic with a formulation choice for patients aged 2 and up. The approval rests on manufacturing and tolerability data rather than new efficacy trials, so it is a label-expansion and convenience play rather than a new clinical readout. It follows the August Japanese pediatric approval and comes after Q2 revenue of $218.3 million with a raised full-year outlook, giving the commercial franchise another lever to defend share against injectable competitors. Modest revenue impact near term; the value is in patient retention and switching flexibility.
At the time of this announcement, BCRX was trading at $8.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $6.23 to $11.22. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.